Expression of genes upregulated in AD lesions decreased in patients treated with dupilumab by 26 % ( 95 % CI , 21 % to 32 % ) and 65 % ( 95 % CI , 60 % to 71 % ) for treatment with 150 and 300 mg , respectively .